UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
CLINICAL RESEARCH

IVIRMA Global

I

IVIRMA Global

Clinical ResearchValencia, Spain
Visit Website

About IVIRMA Global

The world's largest network of assisted reproduction clinics, IVIRMA Global was formed in 2017 when two established fertility leaders, IVI (founded 1990 in Valencia, Spain) and RMA (founded 1999 in the United States), merged to create a single, vertically integrated group spanning Europe, North America and Latin America. Headquartered in Valencia, the group has since grown to more than 200 clinical offices across 15 countries, treating patients who travel from more than 180 countries each year.

Clinical Services Across the Reproductive Medicine Spectrum

IVIRMA Global's clinical portfolio covers the full range of reproductive medicine, including in vitro fertilisation (IVF), intrauterine insemination, egg freezing and fertility preservation, third-party reproduction (donor eggs, donor sperm and gestational carriers), reproductive surgery (laparoscopy, hysteroscopy and myomectomy), and pre-implantation genetic testing. Services are structured to serve heterosexual couples, same-sex couples and single individuals. The group performs more than 200,000 assisted reproduction treatments annually, with approximately 100 babies born every day as a direct result of its programmes.

Research, Science and the IVIRMA Innovation Network

Scientific output is central to the group's identity. IVIRMA Innovation, its dedicated research arm, operates a network of fertility research centres and supports clinical trials, making the group one of the most cited organisations in peer-reviewed reproductive medicine literature. The group employs more than 6,000 people globally, including over 450 physicians and embryologists and more than 500 scientists and researchers. Patient-facing technology includes the Artemis Patient Portal, which centralises treatment management and communication. Financial access programmes, including a CareShare IVF refund programme, reflect a broader commitment to widening access to treatment.

In 2025, IVIRMA Global continued its international expansion, acquiring ART Fertility Clinics in the United Arab Emirates and Saudi Arabia, extending its footprint into the Gulf region. Executive Chairman Dr Antonio Pellicer, one of the original founders of IVI, remains the public face of the group's scientific leadership.

Further information is available at ivirma.com.

Similar Companies

More in Clinical Research

A

ARC Regulatory

Regulatory navigation for IVD and companion diagnostics sits at the core of what ARC Regulatory does. The firm operates as a specialist contract research organisation serving pharmaceutical, diagnostics and laboratory clients that require expert guidance through the clinical and compliance demands of in vitro diagnostic and CDx development. The service portfolio spans four principal disciplines. On the regulatory side, the team supports clients in navigating global frameworks applicable to IVD and CDx programmes. Clinical monitoring is delivered with a global presence, with a particular focus on IVD and CDx study designs. Quality services cover QMS auditing, risk management and QMS implementation, while ARC Research Laboratories provides IVD development and validation using advanced technologies. The CRO offering guides sponsors from strategy through to study close-out across every phase of IVD and CDx clinical development. A dedicated IVD Clinical Study Sponsor Delegation service allows clients to initiate and manage IVD studies through a single trusted partner. The firm's proprietary ARC360 platform is positioned to accelerate clinical performance studies, supporting monitoring of central testing laboratories across the full clinical development life-cycle. Sector coverage reflects the firm's cross-disciplinary positioning. Pharmaceutical clients benefit from support in translational biomarker programmes and early clinical trial authorisations, including risk-based monitoring of central testing laboratories. Diagnostics companies receive R&D compliance support and full-service CRO capability for clinical performance studies. Laboratory clients access analytical testing capabilities aligned to their regulatory obligations. Further information is available at arc-regulatory.co.uk.

View profile
4

4MCS

With a cumulative team experience of over 130 years in clinical trials and the pharmaceutical industry, 4MCS (4 Medical Clinical Solutions) operates as a patient-centred Site Management Organisation dedicated to improving the quality of research in healthcare. The organisation runs its own network of research sites and recruits volunteers from a patient population of over 10 million, giving sponsors direct access to well-characterised cohorts without the delays associated with conventional site activation. The therapeutic breadth across the site's active clinical trial programme spans respiratory conditions including asthma and COPD, cardiovascular disease areas such as atrial fibrillation and hypertension, metabolic and hepatic conditions including fatty liver disease, and a range of central nervous system and dermatological indications. Migraine, depression, general anxiety disorder, myasthenia gravis, lower back pain, psoriasis, and premenopausal effects on sexual health are among the specific areas where the organisation is actively recruiting or conducting clinical research. The patient-centred model that underpins the 4MCS approach prioritises participant experience alongside data quality, with a stated mission linked to improving patient quality of life through evidence generation. The organisation maintains dedicated disease and therapy area specialisms within its leadership and operations structure, supported by an established research site infrastructure across the United Kingdom. Further information is available at 4mcs.co.uk.

View profile
A

AGINKO

Specialising in osteoarticular and inflammation-focused research, AGINKO operates as a contract research organisation (CRO) with a defined focus that distinguishes it from broader-scope service providers. The company concentrates on the musculoskeletal segment, deploying a team of experienced musculoskeletal experts to guide orthopaedic products and compounds through pre-clinical and clinical development pathways. Based in Marly, Switzerland, AGINKO Research AG serves clients across the pharmaceutical, biotechnology, and medical device industries. Its stated mission is to deliver high-quality pre-clinical laboratory services and clinical trial management with a commitment to both customer service and scientific rigour. The combination of pre-clinical and clinical capability within a single specialist organisation allows clients to progress compounds along the regulatory pathway without transferring to a separate provider at each stage. The company's service portfolio spans preclinical research, including disease models; clinical research services; histology and laboratory services; medical consultation and referral; and consulting covering due diligence. Histology services represent a particular operational capability, with preclinical histology slide processing cited among the company's operational activities. Regulatory and clinical process guidance for orthopaedic compounds is a core offering, reflecting the organisation's specialist positioning in the osteoarticular field. AGINKO serves clients globally across multiple countries, providing an international reach from its Swiss base. The company's focus on a defined therapeutic area, rather than a generalist CRO approach, positions it as a reference partner for organisations developing products in musculoskeletal and inflammatory conditions. Further information is available at aginko.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy